Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

241 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Induction chemotherapy with cisplatin, doxorubicin, and cyclophosphamide (CAP) in a combined modality approach for locally advanced and inflammatory breast cancer. Long-term results.
Colozza M, Gori S, Mosconi AM, Anastasi P, de Angelis V, Giansanti M, Mercati U, Aristei C, Latini P, Tonato M. Colozza M, et al. Among authors: de angelis v. Am J Clin Oncol. 1996 Feb;19(1):10-7. doi: 10.1097/00000421-199602000-00003. Am J Clin Oncol. 1996. PMID: 8554028 Clinical Trial.
Prevention of radiotherapy-induced emesis.
Roila F, Ciccarese G, Palladino MA, De Angelis V. Roila F, et al. Among authors: de angelis v. Tumori. 1998 Mar-Apr;84(2):274-8. doi: 10.1177/030089169808400229. Tumori. 1998. PMID: 9620257 Review.
Long-term results of induction chemotherapy followed by concurrent chemotherapy and thoracic irradiation in limited small cell lung cancer.
Maranzano E, Crinò L, Piro F, Meacci L, Bracarda S, de Angelis V, Darwish S, Minotti V, Panizza BM, de Marinis F, Latini P, Tonato M. Maranzano E, et al. Among authors: de marinis f, de angelis v. Lung Cancer. 2002 Jul;37(1):79-85. doi: 10.1016/s0169-5002(02)00028-4. Lung Cancer. 2002. PMID: 12057871 Clinical Trial.
Epirubicin versus CMF as adjuvant therapy for stage I and II breast cancer: a prospective randomised study.
Colozza M, Bisagni G, Mosconi AM, Gori S, Boni C, Sabbatini R, Frassoldati A, Passalacqua R, Bian AR, Rodinò C, Rondini E, Algeri R, Di Sarra S, De Angelis V, Cocconi G, Tonato M. Colozza M, et al. Among authors: de angelis v. Eur J Cancer. 2002 Nov;38(17):2279-88. doi: 10.1016/s0959-8049(02)00452-5. Eur J Cancer. 2002. PMID: 12441265 Clinical Trial.
Evaluation of the prognostic role of vascular endothelial growth factor and microvessel density in stages I and II breast cancer patients.
Ludovini V, Sidoni A, Pistola L, Bellezza G, De Angelis V, Gori S, Mosconi AM, Bisagni G, Cherubini R, Bian AR, Rodinò C, Sabbatini R, Mazzocchi B, Bucciarelli E, Tonato M, Colozza M. Ludovini V, et al. Among authors: de angelis v. Breast Cancer Res Treat. 2003 Sep;81(2):159-68. doi: 10.1023/a:1025755717912. Breast Cancer Res Treat. 2003. PMID: 14572158
Phase II study of weekly paclitaxel and trastuzumab in anthracycline- and taxane-pretreated patients with HER2-overexpressing metastatic breast cancer.
Gori S, Colozza M, Mosconi AM, Franceschi E, Basurto C, Cherubini R, Sidoni A, Rulli A, Bisacci C, De Angelis V, Crinò L, Tonato M. Gori S, et al. Among authors: de angelis v. Br J Cancer. 2004 Jan 12;90(1):36-40. doi: 10.1038/sj.bjc.6601485. Br J Cancer. 2004. PMID: 14710203 Free PMC article. Clinical Trial.
241 results